TITLE

Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection

AUTHOR(S)
Brisson, Marc; Van de Velde, Nicolas; De Wals, Philippe; Boily, Marie-Claude
PUB. DATE
August 2007
SOURCE
CMAJ: Canadian Medical Association Journal;8/28/2007, Vol. 177 Issue 5, p464
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: A vaccine against human papillomavirus (HPV) types 6, 11, 16 and 18 is now licensed for use in Canada and many other countries. We sought to estimate the number needed to vaccinate to prevent HPV-related diseases and death. Methods: A cohort model of the natural history of HPV infection was developed. Model simulations were based on 209 different parameter sets that reproduced Canadian HPV type-specific data for infection, cervical intraepithelial neoplasia, cervical cancer and genital warts. The number needed to vaccinate was calculated as the number of women who would need to be vaccinated to prevent an HPV-related event during their lifetime. Results: Among 12-year-old girls, we estimated that the number needed to vaccinate to prevent an episode of genital warts would be 8 (80% credibility interval [CrI] 5-15) and a case of cervical cancer 324 (80% CrI 195-757). These estimates were based on the assumption that the vaccine procures lifelong protection and that its efficacy is 95%. If vaccine protection is assumed to wane at 3% per year, the predicted number needed to vaccinate would increase to 14 (80% CrI 6-18) and 9080 (80% CrI 1040-does not prevent), respectively. The latter number would be greatly reduced with the addition of a booster dose, to 480 (80% CrI 254-1572). Interpretation: Our model predictions suggest that vaccination with the currently available HPV vaccine may significantly reduce the incidence of genital warts, cervical intraepithelial neoplasia and cervical cancer. However, the benefits (particularly in terms of cervical cancer reduction) are highly dependent on the duration of vaccine protection, on which evidence is currently limited.
ACCESSION #
26595343

 

Related Articles

  • Gardasil benefits boys' health too. Poole, Tracey // New Zealand Doctor;5/4/2011, p27 

    The article discusses how the Gardasil vaccine can also benefit men's health, the use of which has been known to protect women against cervical cancer and genital warts. It says that vaccination with human papillomavirus (HPV) vaccine that includes HPV-11 and HPV-6 will stop most genital warts,...

  • Implementing HPV Vaccinations At A Young Age is Significant For Vaccine Effectiveness.  // JNCI: Journal of the National Cancer Institute;4/3/2013, Vol. 105 Issue 7, p00 

    The article presents a study which evaluates the effectiveness of initial vaccinations for human papillomavirus (HPV) at a younger age to prevent cervical cancer. Swedish researcher Amy Leval and colleagues have determined the incidence rate ratios of genital warts stratified by age at first...

  • Changeover to added protection cervical cancer jab.  // Community Practitioner;Jan2012, Vol. 85 Issue 1, p8 

    The article focuses on the effectiveness of Gardasil in treating cervical cancer, sexually transmitted disease, and genital warts.

  • Expansion of cervical cancer protection through HPV vaccine in BC. Naus, Monika // British Columbia Medical Journal;Sep2012, Vol. 54 Issue 7, p346 

    The article deals with the recommendation of the National Advisory Committee on Immunization to use the human papillomavirus (HPV) vaccine to prevent genital warts aside from using the vaccine for cervical cancer protection. A list of the providers that will deliver the expanded program is...

  • The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia. Uusküla, Anneli; Müürsepp, Andres; Kawai, Kosuke; Raag, Mait; Jürisson, Mikk; Pillsbury, Matthew // BMC Infectious Diseases;2013, Vol. 13 Issue 1, p1 

    Background: This analysis assessed the epidemiological and economic impact of quadrivalent human papillomavirus (HPV4: 6/11/16/18) vaccination in Estonia. Methods: A dynamic transmission model was used to assess the epidemiological and economic impact of the routine vaccination of 12-year-old...

  • HPV vaccine Beyond the hype.  // Consumer Reports;Oct2007, Vol. 72 Issue 10, p47 

    This article discusses the Human Papillomavirus (HPV) vaccine Gardasil and its promise to protect women against four dangerous strains of the virus that causes most cases of cervical cancer and genital warts. Gardasil's manufacturer, Merck, has lobbied to make the vaccine mandatory, and at least...

  • Estimation of the impact of genital warts on health-related quality of life. Woodhall, S.; Ramsey, T.; Cai, C.; Crouch, S.; Jit, M.; Birks, Y.; Edmunds, W. J.; Newton, R.; Lacey, C. J. N. // Sexually Transmitted Infections;Jun2008, Vol. 84 Issue 3, p161 

    Objectives: One of the two new human papillomavirus (HPV) vaccines protects against HPV types 6 and 11, which cause over 95% of genital warts, in addition to protecting against HPV types 16 and 18. In anticipation of HPV vaccine implementation, the impact of genital warts on health-related...

  • What to Do About HPV? Kotz, Deborah // U.S. News & World Report;10/29/2007, Vol. 143 Issue 15, p53 

    The article discusses the debate over inoculating young girls with the human papillomavirus (HPV) vaccine. The vaccine protects against four types of HPV, two of which cause genital warts and two of which are responsible for up to 70 percent of cervical cancers. The concern over giving the...

  • Quantifying the Decisional Satisfaction to Accept or Reject the Human Papillomavirus (HPV) Vaccine: A Preference for Cervical Cancer Prevention. Harper, Diane M.; Irons, Billy B.; Alexander, Natalie M.; Comes, Johanna C.; Smith, Melissa S.; Heutinck, Melinda A.; Handley, Sandra M.; Ahern, Debra A. // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Objective: Only a portion of the US population is willing to consider HPV vaccination to date. The primary aim of this study is to determine the decisional satisfaction associated with HPV vaccination. Study Design: This is a prospective survey conducted at an urban college where women...

  • It will save lives, particularly among the most vulnerable. Lynch, Jo-Ann // American Teacher;May/Jun2007, Vol. 91 Issue 7, p4 

    The author points out that being vaccinated against the human papillomavirus (HPV) would protect many women in the U.S. from contracting cervical cancer. The article also states that the many people who do not have health insurance and avoid medical care would be helped by the vaccine. The...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics